Experimental drug more effective in treating rare kidney disease

October 25, 2018

An experimental drug is more than twice as effective as the standard treatment at reducing a key measure of severity in a rare kidney disease. This is the finding of a phase II clinical trial published online October 25th in the Journal of the American Society of Nephrology.

The new study found that patients with focal segmental glomerulosclerosis (FSGS) taking the drug sparsentan saw a 45 percent reduction in proteinuria--an excess of protein in the urine that suggests poor kidney health. This compared to a 19 percent reduction in the group receiving the typically prescribed irbesartan.

"This is the first large-scale clinical trial of a treatment designed specifically to target FSGS, a rare disorder estimated to affect up to 40,000 people in the United States, and for which there are currently no approved therapies," says principal investigator and lead study author Howard Trachtman, MD, professor in the Department of Pediatrics at NYU School of Medicine and director of the division of pediatric nephrology at Hassenfeld Children's Hospital at NYU Langone. Nearly half of affected patients will progress to end-stage kidney disease, he says.

"Not only could sparsentan become part of the standard of care for patients with FSGS, but there are potential implications for any patient with kidney disease characterized by proteinuria--including the more common IgA nephropathy which affects hundreds of thousands of people worldwide," says Dr. Trachtman.

Nephrologists use proteinuria as a measure, or marker, of the health of FSGS patients. When healthy, the kidneys filter blood, divert waste into urine, and return useful proteins to the bloodstream. FSGS, along with more common kidney diseases, damage the kidney's filtering units, with proteins passing through, and entering the urine to cause scarring in kidney tubules.

With no approved treatments for FSGS, the field has sought to apply to it medications developed to treat other diseases, says Trachtman, including angiotensin II receptor blockers (ARBs) like irbesartan. Initially developed to treat high blood pressure, ARBs are currently used in lieu of an approved FSGS therapy. These drugs act by lowering the blood pressure within the filtering units of the kidney and reducing kidney scarring.

New Approach

For the new study, researchers enrolled 109 patients with FSGS, ages 8-75 in the US and 18-75 in Europe, in a randomized, double-blind, active-controlled trial (DUET) across 44 sites to assess the efficacy and safety of sparsentan. Participants were assigned either escalating doses of sparsentan (200, 400, or 800 mg per day) or irbesartan in 300 mg per day doses over eight weeks. After completing the double-blind eight-week treatment period, patients were able to continue to receive sparsentan in an open-label treatment period.

The study medication, sparsentan, works both as an angiotensin II receptor blocker like irbesartan, and as a blocker of the action of a second protein, endothelin receptor type A (ETA). The study authors had hypothesized that the two actions would together limit the production of molecules that lead to kidney scarring more than irbesartan's single mechanism.

Sparsentan was indeed found to be more effective, and also to have very few serious side effects, with the most common--low blood pressure, dizziness, and swelling--similar in both groups. The research team also found that combining effects in a single molecule increased patients' likelihood of taking their treatment because it reduced the number of pills.

Further study is needed to determine the long-term effects of sparsentan on preservation of kidney function, say the authors. In addition to the open-label treatment period of DUET, a phase III clinical trial (DUPLEX) is actively enrolling patients to determine if sparsentan brings about a sustained reduction of proteinuria.

"The prevalence of FSGS is on the rise, and this combined therapy could offer new hope for patients with this rare kidney disorder who currently face a progressive decline, a high chance of end-stage kidney disease, dialysis or transplantation," says Dr. Trachtman.
In addition to Trachtman, study coauthors include Olga Zhdanova, MD, in the Department of Medicine, Division of Nephrology at NYU School of Medicine; Peter Nelson, MD; Sharon Adler, MD; Kirk N. Campbell, MD; Abanti Chaudhuri, MD; Vimal K. Derebail, MD; Giovanni Gambaro, MD, PhD; Loreto Gesualdo, MD; Debbie S. Gipson, MD; Jonathan Hogan, MD; Kenneth Lieberman, MD; Brad Marder, MD; Kevin E. Meyers, MD; Esmat Mustafa, MD; Jai Radhakrishnan, MD; Tarak Srivastava, MD; Miganush Stepanians, PhD; Vladimir Tesar, MD; and Radko Komers, MD, PhD, on behalf of the DUET study group.

Sparsentan is manufactured by Retrophin, Inc., the biopharmaceutical company that funded the current clinical trial. Dr. Trachtman served as an unpaid consultant for Retrophin, has reported receiving consultancy fees from Kaneka Inc, Otsuka, and ChemoCentryx and was a consultant in the past to Genzyme and Optherion. All relationships are being managed in accordance with the policies of NYU School of Medicine.

NYU Langone Health / NYU School of Medicine

Related Blood Pressure Articles from Brightsurf:

Children who take steroids at increased risk for diabetes, high blood pressure, blood clots
Children who take oral steroids to treat asthma or autoimmune diseases have an increased risk of diabetes, high blood pressure, and blood clots, according to Rutgers researchers.

High blood pressure treatment linked to less risk for drop in blood pressure upon standing
Treatment to lower blood pressure did not increase and may decrease the risk of extreme drops in blood pressure upon standing from a sitting position.

Changes in blood pressure control over 2 decades among US adults with high blood pressure
National survey data were used to examine how blood pressure control changed overall among U.S. adults with high blood pressure between 1999-2000 and 2017-2018 and by age, race, insurance type and access to health care.

Transient increase in blood pressure promotes some blood vessel growth
Blood vessels are the body's transportation system, carrying oxygen and nutrients to cells and whisking away waste.

Effect of reducing blood pressure medications on blood pressure control in older adults
Whether the amount of blood pressure medications taken by older adults could be reduced safely and without a significant change in short-term blood pressure control was the objective of this randomized clinical trial that included 534 adults 80 and older.

Brain blood flow sensor discovery could aid treatments for high blood pressure & dementia
A study led by researchers at UCL has discovered the mechanism that allows the brain to monitor its own blood supply, a finding in rats which may help to find new treatments for human conditions including hypertension (high blood pressure) and dementia.

Here's something that will raise your blood pressure
The apelin receptor (APJ) has been presumed to play an important role in the contraction of blood vessels involved in blood pressure regulation.

New strategy for treating high blood pressure
The key to treating blood pressure might lie in people who are 'resistant' to developing high blood pressure even when they eat high salt diets, shows new research published today in Experimental Physiology.

Arm cuff blood pressure measurements may fall short for predicting heart disease risk in some people with resistant high blood pressure
A measurement of central blood pressure in people with difficult-to-treat high blood pressure could help reduce risk of heart disease better than traditional arm cuff readings for some patients, according to preliminary research presented at the American Heart Association's Hypertension 2019 Scientific Sessions.

Heating pads may lower blood pressure in people with high blood pressure when lying down
In people with supine hypertension due to autonomic failure, a condition that increases blood pressure when lying down, overnight heat therapy significantly decreased systolic blood pressure compared to a placebo.

Read More: Blood Pressure News and Blood Pressure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.